Abstract:Epigenetic alterations play an important role in the development of acute myeloid leukemia (AML) by silencing of genes that suppress leukemogenesis and differentiation. One of the key epigenetic changes in AML is gene silencing by DNA methylation. The importance of this alteration is illustrated by the induction of remissions in AML by 5-aza-2'-deoxycytidine (5-AZA-CdR, decitabine), a potent inhibitor of DNA methylation. However, most patients induced into remission by 5-AZA-CdR will relapse, suggesting that a second agent should be sought to increase the efficacy of this epigenetic therapy. An interesting candidate for this purpose is 3-deazaneplanocin A (DZNep). This analog inhibits EZH2, a histone methyltransferase that trimethylates lysine 27 histone H3 (H3K27me3), a marker for gene silencing. This second epigenetic silencing mechanism also plays an important role in leukemogenesis as shown in preclinical studies where DZNep exhibits potent inhibition of colony formation by AML cells. We reported previously that 5-AZA-CdR in combination with DZNep exhibits a synergistic antineoplastic action against human HL-60 AML cells and the synergistic activation of several tumor suppressor genes. In this report, we showed that this combination also induced a synergistic activation of apoptosis in HL-60 cells. The synergistic antineoplastic action of 5-AZA-CdR plus DZNep was also observed on a second human myeloid leukemia cell line, AML-3. In addition, 5-AZA-CdR in combination with the specific inhibitors of EZH2, GSK-126, or GSK-343, also exhibited a synergistic antineoplastic action on both HL-60 and AML-3. The combined action of 5-AZA-CdR and DZNep on global gene expression in HL-60 cells was investigated in greater depth using RNA sequencing analysis. We observed that this combination of epigenetic agents exhibited a synergistic activation of hundreds of genes. The synergistic activation of so many genes that suppress malignancy by 5-AZA-CdR plus DZNep suggests that epigenetic gene silencing by DNA and histone methylation plays a major role in leukemogenesis. Targeting DNA and histone methylation is a promising approach that merits clinical investigation for the treatment of AML.

5-Aza-2 '-Deoxycytidine Reactivates Gene Expression Via Degradation of Prb Pocket Proteins

The effects of 5-Aza-2-deoxycytidine, a methylation inhibitor, on the proliferation of androgen-sensitive prostate cancer cell line, and on the regulation of methylation of glutathione s-transferase P1 and retinoic acid receptorβ2 gene

Effect of 5-Aza-2′-deoxycytidine in High-Risk Myelodysplasia Cells in Vitro.

[SHP-1 Gene's Methylation Status of Daudi Lymphoma Cell and the Demethylation Effect of 5-Aza-2'-deoxycytidine].

[The Study of 5-Aza-2'-deoxycytidine on Transcription Regulation of P16/cdkn2 Gene Demethylation in RKO Human Colorectal Cell Line].

5-Aza-Cytidine Enhances Terminal Polyadenylation Site Usage for Full-Length Transcripts in Cells

5-Aza-2′-deoxycytidine Activates the P53/p21waf1/cip1 Pathway to Inhibit Cell Proliferation

[The Re-Expression of P15(ink4b) Gene in Leukemia Cells Induced by in Vitro DNA Methyltransferase and Histone Deacetylase Inhibition].

Effects of 5-Aza-2'-deoxycytidine on Biological Behaviors and the RASSF1A Gene Expression of Human Lung Carcinoma Cell Lines H460

Methyltransferase Inhibition Enables Tgf β Driven Induction of CDKN2A and B in Cancer Cells

5-Aza-2'-deoxycytidine induces retinoic acid receptor-beta(2) demethylation and growth inhibition in esophageal squamous carcinoma cells.

5-Aza-2 '-Deoxycitydine Induces Demethylation and Up-Regulates Transcription of P16(Ink4a) Gene in Human Gastric Cancer Cell Lines

Effects of 5-Aza-2'-deoxycitydine on Proliferation of Prostate Cancer Cell Line PC3 and Transcriptional Regulation of Tumor Suppressor Gene GSTP1 and RASSF1A

Epigenetic Silencing of a Ca2+-regulated Ras GTPase-activating Protein RASAL Defines a New Mechanism of Ras Activation in Human Cancers

5-aza-2'-deoxycytidine activates iron uptake and heme biosynthesis by increasing c-Myc nuclear localization and binding to the E-boxes of transferrin receptor 1 (TfR1) and ferrochelatase (Fech) genes.

An ATM- and Rad3-related (ATR) Signaling Pathway and a Phosphorylation-Acetylation Cascade Are Involved in Activation of P53/p21waf1/cip1 in Response to 5-Aza-2′-deoxycytidine Treatment

The Epigenetic Modifier PRDM5 Functions As a Tumor Suppressor Through Modulating WNT/β-catenin Signaling and is Frequently Silenced in Multiple Tumors.

Effects of 5-Aza-2'-deoxycytidine on the carcinogenesis of colorectal cancer in mouse and thein vivo expression of p16/CDKN2 mRNA

5-Aza-2′-deoxycytidine induces retinoic acid receptor-β2 demethylation and growth inhibition in esophageal squamous carcinoma cells

RUNX3 Gene Promoter Demethylation by 5-Aza-cdr Induces Apoptosis in Breast Cancer MCF-7 Cell Line

Inhibition of DNA and Histone Methylation by 5-Aza-2′-Deoxycytidine (Decitabine) and 3-Deazaneplanocin-A on Antineoplastic Action and Gene Expression in Myeloid Leukemic Cells